Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care SettingCompleted
NCT05073783N/AUpdated Feb 14, 2024
Sponsor: Sanofi
Pompe Disease · Mucopolysaccharidosis Type I (MPS I)
Italy
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY DiseaseTerminated
NCT04912427Phase 1Updated Feb 9, 2024
Sponsor: Washington University School of Medicine
Multiple Myeloma
United States
Pediatric and Ambulatory Research in Infectious DiseasesRecruiting
NCT04471493N/AUpdated Feb 8, 2024
Sponsor: Association Clinique Thérapeutique Infantile du val de Marne
Otitis · Bronchiolitis · Influenza · Pharyngitis
France
Pediatric Pertussis in Ambulatory SettingsRecruiting
NCT04807712N/AUpdated Feb 8, 2024
Sponsor: Association Clinique Thérapeutique Infantile du val de Marne
Pertussis/Whooping Cough · Children, Only · Ambulatory
France
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)Completed
NCT03682770Phase 2Updated Feb 7, 2024
Sponsor: Regeneron Pharmaceuticals
Peanut Allergy
United States
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)Completed
NCT02903160Phase 2Updated Feb 7, 2024
Sponsor: Icahn School of Medicine at Mount Sinai
Prostate Cancer
United States
Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell CancerTerminated
NCT02478502Phase 2Updated Feb 2, 2024
Sponsor: University Hospital, Akershus
Testicular Cancer
Denmark, Italy, Norway, Sweden
Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.Completed
NCT01041508Phase 1Updated Feb 1, 2024
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
Leukemia Lymphoblastic, Acute · Acute Myeloid Leukemia · Neoplasm Recurrent
United States
Optimising Protection for Pregnant Women and Infants With Maternal VaccinationUnknown
NCT03457194N/AUpdated Jan 31, 2024
Sponsor: Women's and Children's Hospital, Australia
Obesity
Australia
Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate TransplantationCompleted
NCT02513186Phase 1Updated Jan 29, 2024
Sponsor: Sanofi
Plasma Cell Myeloma
France, Germany, Italy, Spain
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne VulgarisCompleted
NCT05131373Phase 1Updated Jan 24, 2024
Sponsor: Sanofi Pasteur, a Sanofi Company
Acne Vulgaris · Acne
Germany
Pharmacokinetics and Safety of SAR441236Terminated
NCT03705169Phase 1Updated Jan 12, 2024
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
United States
Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During PregnancyCompleted
NCT04023708N/AUpdated Jan 10, 2024
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Virus Infection
Brazil
A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor MetabolizersCompleted
NCT06188325Phase 1Updated Jan 10, 2024
Sponsor: Sanofi
Gaucher's Disease
United States
Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial FibrillationCompleted
NCT05279833N/AUpdated Jan 9, 2024
Sponsor: Sanofi
Atrial Fibrillation
France
A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the MouthCompleted
NCT06193304Phase 1Updated Jan 5, 2024
Sponsor: Sanofi
Gaucher's Disease
United States
Understanding Magnetic Resonance Imaging in Multiple SclerosisCompleted
NCT03872583NAUpdated Jan 3, 2024
Sponsor: Universitätsklinikum Hamburg-Eppendorf
Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting · Clinically Isolated Syndrome
Germany
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)Completed
NCT01524705Phase 4Updated Dec 29, 2023
Sponsor: University of Washington
Type 2 Diabetes
United States
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)Completed
NCT04417894Phase 3Updated Dec 22, 2023
Sponsor: Regeneron Pharmaceuticals
Moderate to Severe Atopic Hand and Foot Dermatitis
United States, Germany, Japan, Poland
Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic DermatitisCompleted
NCT03912259Phase 3Updated Dec 19, 2023
Sponsor: Sanofi
Atopic Dermatitis
China
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersCompleted
NCT03673462Phase 3Updated Dec 14, 2023
Sponsor: Sanofi Pasteur, a Sanofi Company
Healthy Volunteers (Meningococcal Infection)
United States, Puerto Rico
Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric CancerCompleted
NCT01515748Phase 3Updated Dec 13, 2023
Sponsor: Sanofi
Gastric Cancer
South Korea
A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center StudyCompleted
NCT06165276Phase 1Updated Dec 11, 2023
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Immunization
Study of the Tolerability of Different SAR153191 Drug Products, That Differ With Respect to Manufacturing Processes and Formulation, at Different Concentrations and Doses in Healthy Male SubjectsCompleted
NCT06159452Phase 1Updated Dec 6, 2023
Sponsor: Sanofi
Rheumatoid Arthritis
Development of an Assessment Tool for Health-related Quality of Life in Children and Adolescents With Pompe DiseaseCompleted
NCT04724213NAUpdated Dec 5, 2023
Sponsor: University Children's Hospital, Zurich
Pompe Disease
Switzerland

Previous page Next page